Sankala Group’s Immunovant IMVT Stock Holding History

Sankala Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.71K	Hold	150	–	–	﹤0.01%	453
2025 Q4	$4.16K	Buy	+150	New	+$3.35K	﹤0.01%	460

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sankala Group's IMVT Position: Q1 2026 in Review

Sankala Group held its Immunovant (IMVT) position steady in Q1 2026 at 150 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #453.

Sankala Group first reported a position in IMVT in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.16K in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Sankala Group held 150 shares of Immunovant worth $3.71K as of Q1 2026.
Sankala Group left its Immunovant share count unchanged in Q1 2026.
Immunovant made up ﹤0.01% of Sankala Group's portfolio in Q1 2026, its #453 holding.
Sankala Group first reported a position in Immunovant in Q4 2025 and has held it in 2 quarters since.
Sankala Group's Immunovant position peaked at $4.16K in Q4 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.